Global Pandemic Drives Unprecedented Need to Grow Canada’s Life Science Leadership

September 14, 2020
adMare BioInnovations

adMare Academy Announces New Executive Institute Cohort Vancouver and Montreal, Canada – September 14th, 2020: After receiving a record number of applications from across Canada, adMare BioInnovations (adMare) is pleased to announce the successful applicants for its 2020-2021 Executive Institute cohort. Launched in 2018 with the support of Pfizer Canada, this 10-month, highly-focused executive development … Continue reading Global Pandemic Drives Unprecedented Need to Grow Canada’s Life Science Leadership

Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors

September 10, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer of Principia Biopharma, Inc. (NASDAQ: PRNB), to the company’s Board of Directors. Mr. Babler brings decades of experience in business … Continue reading Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors

Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

September 10, 2020
Aurinia Pharmaceuticals Inc.

September 10, 2020, VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences: H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020 at 10:30 a.m. EDT. … Continue reading Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

September 9, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 9:30 a.m. Eastern Time. A live … Continue reading Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System

September 8, 2020
Kardium Inc.

September 8, 2020 – VANCOUVER, British Columbia – Kardium Inc. announced the first commercial procedures with the Globe Mapping and Ablation System. The Globe System is the most complete solution for the treatment of atrial fibrillation (AF) – the world’s most common heart rhythm disorder, affecting more than 37 million people. The first patients were … Continue reading Kardium Marks First Commercial Procedures of Globe® Mapping and Ablation System

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2020
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price … Continue reading Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

September 2, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – September 2, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the fiscal year ended June 30, 2020, on Tuesday, … Continue reading InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

Join Us at the 2020 LifeSciences BC Annual Award Winners Recognition Event

September 2, 2020
LifeSciences BC

VANCOUVER, BC – September 2, 2020 – On February 26, 2020, LifeSciences BC announced the recipients of the 22nd Annual LifeSciences BC Awards. These awards are presented annually to recognize talented individuals and organizations that represent the life sciences ecosystem in B.C. which includes academia, health institutions, research & development, SMEs, government and industry. This … Continue reading Join Us at the 2020 LifeSciences BC Annual Award Winners Recognition Event

Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million

September 1, 2020
Kintara Therapeutics, Inc.

– Launches Strategic Growth Initiative of Expanded Late-stage Oncology Pipeline – SAN DIEGO, Sept. 1, 2020 /PRNewswire/ — Kintara Therapeutics, Inc. (“Kintara” or the “Company”) (Nasdaq: KTRA) announced today the final closing of its previously announced private placement of Series C Convertible Preferred Stock (the “Preferred Stock”) to accredited investors. Including the previously announced closings, … Continue reading Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020

August 28, 2020
LivaNova PLC

LivaNova, a market-leading medical technology and innovation company, will present an ePoster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The LivaNova VITARIA® System delivers ART via mild electrical impulses applied to … Continue reading LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020